Spero Therapeutics (SPRO) EBT Margin (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly EBT Margin came in at 234.99% in Q4 2025, up 27514652.0% YoY from N/an in Q4 2024, and up 100.2% on a QoQ basis from 115558.33% in Q1 2025.
Spero Therapeutics (SPRO) EBT Margin (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of EBT Margin data on file, last reported at 234.99% in Q4 2025.
- Quarterly EBT Margin rose 27514652.0% year-over-year to 234.99% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 899.3% (up 94983.0% YoY) and the FY2025 annual result came in at 43.06%, up 5149401.0% from the prior year.
- EBT Margin improved to 234.99% in Q4 2025, from 115558.33% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1044.41% in Q4 2021 to a low of 274911.54% in Q4 2024.
- A 5-year average of 25393.71% and a median of 898.05% in 2021 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin slumped 27511334 bps — and 2025, when it jumped 27514652 bps.
- Tracing SPRO's EBT Margin over 5 years: stood at 1044.41% in 2021, then tumbled by 153 bps to 550.63% in 2022, then jumped by 137 bps to 201.8% in 2023, then sank by 136329 bps to 274911.54% in 2024, then surged by 100 bps to 234.99% in 2025.
- The last three EBT Margin figures came in at 234.99% (Q4 2025), 115558.33% (Q1 2025), and 274911.54% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 12.09% |
| 10 | Spero Therapeutics | 72.23 Mn | 21.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,862.02% |
| Dec 31, 2025 | 234.99% |
| Mar 31, 2025 | -115,558.33% |
| Dec 31, 2024 | -274,911.54% |
| Sep 30, 2024 | -25,009.23% |
| Jun 30, 2024 | -175.19% |
| Mar 31, 2024 | -9,045.00% |
| Dec 31, 2023 | 201.80% |
| Sep 30, 2023 | -3.87% |
| Jun 30, 2023 | -438.48% |
| Mar 31, 2023 | -5,948.43% |
| Dec 31, 2022 | -550.63% |
| Sep 30, 2022 | -1,093.90% |
| Jun 30, 2022 | -2,910.04% |
| Mar 31, 2022 | -13,800.00% |
| Dec 31, 2021 | 1,044.41% |
| Sep 30, 2021 | -7,871.47% |
| Jun 30, 2021 | -702.20% |
| Mar 31, 2021 | -549.67% |
| Sep 30, 2020 | -77,239.47% |